GGrantIndex
Sort

39,280 grants matching leukemia

Enhancing cytarabine efficacy in leukemia through CDK8/19 inhibition

$299,891
Donald C. Porter · Senex Biotechnology, Inc. · R43 · FY2017 · CA

Development and Applications of 'Designer Chromatin'

$299,888
Tom W Muir · Princeton University · R01 · FY2014 · GM

Molecular concepts that monitor methionine metabolism

$299,883
Peter Kaiser · University Of California-Irvine · R01 · FY2021 · GM

MECHANISM(S) OF CHEMICAL LEUKEMOGENESIS

$299,880
University Of Colorado Denver · R01 · FY2002 · ES

Retrovirus Assembly and Maturation

$299,875
Alan Rein · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Human T cell Lymphotropic Virus Vaccine development

$299,860
Glen N Barber · Stinginn, Llc · R41 · FY2022 · AI

Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers

$299,823
Zhongzhi Wu · Seak Therapeutics, Llc · R43 · FY2019 · CA

Role of PBX Proteins in Hematopoiesis and Growth Control

$299,800
Michael L Cleary · Stanford University · R01 · FY2008 · CA

Eastern Cooperative Oncology Group

$299,793
Indiana Univ-Purdue Univ At Indianapolis · U10 · FY2004 · CA

Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing

$299,790
Jesse J Salk · Twinstrand Biosciences, Inc. · R44 · FY2018 · CA

Human Tumor Analyses

$299,789
William M Grady · University Of Washington · P01 · FY2011 · CA

INK4 FAMILY OF CDK INHIBITORS

$299,786
University Of North Carolina Chapel Hill · R01 · FY2001 · CA

Pharmacological rejuvenation of human hematopoietic stem cells

$299,781
James C Mulloy · Mogling Bio Inc · R43 · FY2024 · HL

Regulators of Cancer-Specific DNA Hypermethylation.

$299,720
Jean-Pierre J Issa · Temple Univ Of The Commonwealth · R01 · FY2013 · CA

Novel Roles of p53 & ROS in Therapy of Refractory CLL

$299,699
Peng Huang · University Of Tx Md Anderson Can Ctr · R01 · FY2010 · CA

Novel Roles of p53 & ROS in Therapy of Refractory CLL

$299,699
Peng Huang · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA

Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

$299,687
William A Frazier · Vasculox, Inc. · R41 · FY2013 · CA

Methodology for Identification of Substrate-Competitive Kinase Inhibitors

$299,667
Matthew B Soellner · University Of Michigan At Ann Arbor · R01 · FY2009 · GM

Development of a chemically regulated immunotherapy for B-cell malignancies

$299,600
Erin Forbes Simonds · Soteria Biotherapeutics, Inc. · R43 · FY2019 · CA

Role of PBX Proteins in Hematopoiesis and Growth Control

$299,598
Michael L Cleary · Stanford University · R01 · FY2007 · CA

Regulation of hematopoietic stem cell differentiation

$299,591
Iannis Aifantis · New York University School Of Medicine · R01 · FY2012 · CA

Regulation of hematopoietic stem cell differentiation

$299,591
Iannis Aifantis · New York University School Of Medicine · R01 · FY2011 · CA

Genomics of Acute Myelogenous Leukemia (AML): Relapse and Resistance Factors

$299,591
John F Dipersio · Washington University · P01 · FY2010 · CA

Pathobiology of Cancer at the Host and Population Level

$299,581
Laurie H Glimcher · Harvard School Of Public Health · T32 · FY2011 · CA

EAGER: Biomanufacturing the hematopoietic stem cell niche

$299,578
Brendan Harley · University Of Illinois At Urbana-Champaign · · FY2015 · ENG